# A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age

> **NCT05903183** · PHASE2 · COMPLETED · sponsor: **Icosavax, Inc.** · enrollment: 264 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** IVX-A12
- **BIOLOGICAL:** IVX-A12
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05903183
- **Lead sponsor:** Icosavax, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-15
- **Primary completion:** 2023-06-05
- **Final completion:** 2024-10-25
- **Target enrollment:** 264 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05903183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05903183, "A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT05903183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*